Pfizer's Trispecific Antibody Tilrekimig Hits EASI-75 in Phase 2 AD
Tilrekimig, a first-in-class trispecific antibody targeting IL-4, IL-13 and TSLP, delivered EASI-75 rates up to 62.5% at Week 16 in a Phase 2 atopic dermatitis trial.
Topic
Eadv Congress
Topic
Eadv Congress
Lutris Pharma Reports Durable Phase 2 Benefit for LUT014 Gel in EGFR Inhibitor Rash
Lutris Pharma presented updated Phase 2 data at EADV showing durable, mechanism-directed benefit of LUT014 topical gel for acneif…
EADV Congress 2026 Opens: Six Day-One Headlines for Dermatology
EADV Congress 2026 opened with a six-headline day-one recap spanning late-breaking data and management updates across dermatology…